GHK-Cu
Matrix and Epithelial
£28.00per vial
Awaiting batch
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
GHK-Cu cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
GHK-Cu is a research peptide listed in the UK for in-vitro laboratory use only. It is not a medicine and it is not for human or veterinary use. This page is the GHK-Cu listing for Protocol Peptides UK.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma. Laboratory work examines it in extracellular matrix remodelling, collagen and glycosaminoglycan synthesis models, and gene-expression modulation, where its copper-binding behaviour is the defining variable.
Also known as Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
- UK DISPATCH
- TRACKED SHIPPING
- COA ON RELEASE
- SECURE PAYMENT
Compound details
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma. Laboratory work examines it in extracellular matrix remodelling, collagen and glycosaminoglycan synthesis models, and gene-expression modulation, where its copper-binding behaviour is the defining variable.
GHK-Cu is a naturally occurring tripeptide that binds copper(II) with high affinity. The peptide was first isolated from human plasma, where its concentration declines measurably with donor age, and that observation is what put it into the tissue-remodelling research literature. The copper coordination is not incidental to the mechanism, it is the mechanism: the complex acts as a copper carrier, and the metal is required for the enzymatic activity the compound is studied against.
- Molecular weight
- 400.9 g/mol
- Sequence
- GHK, complexed with copper(II)
- Presentation
- Sealed 3ml vial
Molecular weight source: PubChem CID 139035031 (copper tripeptide, the copper(II) complex). The free tripeptide ligand alone is 340.4 g/mol, PubChem CID 73587.. View the PubChem record
GHK-Cu is a naturally occurring tripeptide that binds copper(II) with high affinity. The peptide was first isolated from human plasma, where its concentration declines measurably with donor age, and that observation is what put it into the tissue-remodelling research literature. The copper coordination is not incidental to the mechanism, it is the mechanism: the complex acts as a copper carrier, and the metal is required for the enzymatic activity the compound is studied against.
Preclinical investigations examine GHK-Cu in extracellular matrix frameworks, including collagen and decorin synthesis models and the balance between matrix metalloproteinases and their tissue inhibitors. Separate work examines it in gene-expression modulation, where transcriptomic studies report broad shifts in expression profile, and in antioxidant and copper-dependent enzymatic system research. Dermal, follicular, and angiogenesis models are the common experimental contexts.
One distinction matters for anyone reading this page from a cosmetic search: GHK-Cu is widely formulated into finished cosmetic serums, which are regulated in Great Britain under the cosmetic products regime and are a different category of item entirely. This listing is not a cosmetic product. It is a research-grade compound catalogued for laboratory use, and it is neither formulated nor labelled for topical application to a person. No therapeutic, diagnostic, cosmetic or clinical conclusion is drawn from any study referenced above, and none should be inferred.
GHK-Cu is listed in a sealed 3ml vial, at 50mg and 100mg. The solution carries the characteristic blue colour of the copper(II) complex.
When a batch is released, it is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry. Those are the two analytical methods used, and no other method is claimed.
When a batch is released, the batch number on the vial resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date. The document is published before the batch enters the catalogue. Specimen documents on this site are for demonstration only and are not genuine laboratory reports.
When a batch is released, it is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
GHK-Cu
GH5612Specimen record. Not a genuine laboratory report.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 99.2% |
| Identity | Mass spectrometry | Consistent with expected mass |
HPLC
Purity by chromatography
ON RELEASE
MASS SPECTROMETRY
Identity confirmation
ON RELEASE
PUBLIC COA
Each released batch number resolves to its Certificate of Analysis
COMMITTED
Research Use Only
GHK-Cu is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about GHK-Cu. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
When analytical results are published for GHK-Cu, they relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch. Specimen documents are for demonstration only and are not genuine laboratory reports.
Jurisdiction Notice
GHK-Cu cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Every released batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number then resolves to the report. Specimen documents on this site are for demonstration only.
For laboratory research only. Not for human consumption. No medical claims.
